

11 October 2022

ASX Release

**Oventus Medical Ltd
(Administrators appointed)
ACN 608 393 282 ('Company' or 'Oventus')**

Appointment of Director

We refer to the appointment of Michael McCann and Graham Killer of Grant Thornton as Administrators of Oventus and its Australian registered subsidiaries, Oventus Manufacturing Pty Ltd and Oventus CRM Pty Ltd, on 14 June 2022 (**Administrators**).

Pursuant to the powers granted to the Administrators under section 442A(b) the *Corporations Act 2001* (Cth), the Administrators confirm the appointment of Dr Melvyn Bridges as a director of each of Oventus and its two Australian registered subsidiaries, Oventus Manufacturing Pty Ltd and Oventus CRM Pty Ltd.

Dr Bridges has over 35 years' experience founding and building international life science, diagnostic and medical device companies and commercialising a wide range of Australian technologies.

It is anticipated that Dr Bridges will be appointed to the role of Chief Executive Officer and Executive Chairman. As at the date of this ASX Announcement, the terms of Dr Bridges role are yet to be finalised. Once this is complete, the Administrators will provide an update to the market.

Dr Bridges says *"I am looking forward to leading Oventus through its proposed recapitalisation process and realising the extensive commercial potential of the O2Vent™ device in the treatment of sleep apnoea"*.

An ASX Appendix 3X accompanies this ASX Announcement.

Shareholder Questions

For further information in relation to the external administration of Oventus or the information set out above, the contact details of the Administrators are given below:

Email: Oventus@au.gt.com

ENDS –

This announcement has been approved for lodgement by the Administrators.

While Oventus remains admitted to the ASX, the Administrators will continue to provide updates to shareholders over the course of the administration by way of announcements to the ASX.

